The Medications · March 23, 2026 · 7 min · By Maeve Castellucci
Medical weight loss in the GLP-1 era
A new class of medications has changed the conversation, here is the honest picture.
Weight management has been transformed in recent years by GLP-1 receptor agonist medications, and understanding what they do and do not do cuts through both the hype and the skepticism around them.
These medications, originally developed for diabetes, mimic a gut hormone that regulates appetite and fullness, leading to reduced food intake and significant weight loss for many people. They have made medically supervised weight loss far more effective than diet and willpower alone for those who qualify, and they are reshaping how obesity is treated as the chronic medical condition it is rather than a failure of discipline. For appropriate patients, the results can be substantial.
The honest caveats matter. These are medical treatments with side effects, costs, and considerations that require physician supervision, not casual use. Weight often returns if the medication is stopped without sustained lifestyle change, so they work best alongside nutrition and activity habits rather than instead of them. They are tools within a comprehensive plan, suited to specific patients, not a universal shortcut. The broader shift they represent is positive: treating weight as a medical issue deserving real treatment and support. For someone struggling with weight despite genuine effort, a medically supervised program, which may or may not include these medications, is worth exploring with a qualified clinician who tailors it to your health. None of it lasts without the foundation covered in sustainable weight loss beyond the scale.
Related reading: Choosing a surgeon for post-weight-loss contouring.
Further reading: Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis (Obes Rev 2024); GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications (Adv Ther 2023); Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis (Endocr Pract 2024).